Pioneering Miniproteins Therapy

EniacPharma's self-correcting AI platform transforms protein drug discovery by designing miniproteins with unprecedented efficiency. Our integrated system combines generative and agentic AI to autonomously generate, evaluate, and refine candidates through iterative cycles, reducing design time by 10x and wet lab costs by 90%.

EniacPharma's miniproteins address critical unmet medical needs in oncology, immunology, metabolic disorders, and fibrosis. Our AI-designed therapeutics combine the precision targeting of biologics with the stability and manufacturability of small molecules, unlocking treatment possibilities for diseases that have resisted conventional drug approaches.

Through our advanced computational platform, we design miniprotein candidates with optimal binding affinity, potency, and safety profiles—all before entering costly laboratory testing. This approach dramatically accelerates development timelines and reduces capital requirements, bringing life-changing therapies to patients faster.

The cosmetics industry is evolving beyond traditional ingredients toward molecularly-precise actives that deliver measurable results. Our miniproteins target the fundamental mechanisms of skin aging—collagen loss, loss of elasticity, and cellular damage—with unprecedented specificity and efficacy.

Designed for premium skincare brands seeking scientifically-differentiated products, our miniprotein actives offer proven mechanisms of action, exceptional stability, and compelling consumer narratives. With our Hong Kong base providing direct access to the dynamic Asian beauty market, we partner with forward-thinking brands to bring next-generation anti-aging solutions to discerning consumers worldwide.